The Preserving Access to Cost Effective Drugs (PACED) Act (S. 2514) would bar patent holders from asserting tribal immunity to escape Patent Trial and Appeal Board review proceedings. Allergen irked members of Congress and affordable drug advocates last year when it transferred patents on its …
